Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

OBJECTIVE: To describe detailed MRI results from 2 head-to-head phase III trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis Study I (CARE-MS I; NCT00530348) and Study II (CARE-MS II; NCT00548405), of alemtuzumab vs subcutaneous interferon β-1a (SC IFN-β-1a) in patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurology
Main Authors: Arnold, Douglas L., Fisher, Elizabeth, Brinar, Vesna V., Cohen, Jeffrey A., Coles, Alasdair J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Stojanovic, Miroslav, Weiner, Howard L., Lake, Stephen L., Margolin, David H., Thomas, David R., Panzara, Michael A., Compston, D. Alastair S.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5075976/
https://ncbi.nlm.nih.gov/pubmed/27590291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000003169
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados